Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
View Patent ↗Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
1. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a mammal comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the mammal wherein the PYY formulation is comprised of a solubilizing agent, a chelating agent, a polyol, L-α-phosphatidylcholine didecanoyl (DDPC) and a PYY peptide wherein the PYY peptide is comprised of the amino acid sequence of SEQ ID NO: 2.
2. The method of claim 1 wherein the formulation is an aqueous PYY formulation.
3. The method of claim 2 wherein the aqueous PYY formulation has a pH of about of about 3–6.
4. The method of claim 3 wherein the pH of the aqueous PYY formulation is 5.0±0.3.
5. The method of claim 1 wherein a dose containing 50 μg to 800 μg of a PYY peptide is administered to the mammal.
6. The method of claim 5 wherein a dose containing 100 μg to 400 μg is administered to the mammal.
7. The method of claim 6 wherein a dose containing 150 μg to 200 μg is administered to the mammal.
8. The method of claim 1 wherein the mammal is a human.
9. The method for inducing appetite suppression of claim 1 wherein the formulation is further comprised of at least two polyols.
10. The method for inducing appetite suppression of claim 9 wherein the polyols are selected from the group consisting of sucrose, mannitol, sorbitol, lactose, L-arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, trehalose, D-galactose, lactulose, cellobiose, gentibiose, glycerin and polyethylene glycol.
11. The method of claim 10 wherein the polyols are lactose and sorbitol.
12. The method of claim 1 wherein the chelating agent is ethylene diamine tetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA).
13. The method of claim 12 wherein the chelating agent is ethylenediamine tetraacetic acid (EDTA).
14. The method of claim 1 wherein the solubilizing agent is selected from the group consisting of a cyclodextran, hydroxypropyl-β-cyclodextran, sulfobutylether-β-cyclodextran and methyl-β-cyclodextrin.
15. The method of claim 14 wherein the solubilizing agent is a cyclodextrin.
16. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a mammal comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the mammal wherein the PYY formulation is comprised of methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and a PYY peptide wherein the PYY peptide is comprised of the amino acid sequence of SEQ ID NO: 2.
17. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a human comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the human wherein the PYY formulation is comprised of water, sodium citrate, citric acid, methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and PYY(3–36) (SEQ ID NO: 2), wherein the formulation has a pH of about 5.0±0.3.
18. The method of claim 17 wherein the human is administered a dose containing from 50 μg to about 800 μg of PYY(3–36) (SEQ ID NO: 2).
19. The method of claim 17 wherein the human is administered a dose containing from 100 μg to about 400 μg of PYY(3–36) (SEQ ID NO: 2).
20. The method of claim 17 wherein the human is administered a dose containing from 150 μg to about 200 μg of PYY(3–36) (SEQ ID NO: 2).
21. The method of claim 17 , wherein the formulation is further comprised of a preservative selected from the group consisting of chlorobutanol and benzalkonium chloride.
22. The method of claim 21 wherein the preservative is chlorobutanol.
23. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a human comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the human wherein the PYY formulation is comprised of water, sodium citrate, citric acid, methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and PYY(3–36) (SEQ ID NO: 2), wherein the formulation has a pH of about 5.0±0.3 and wherein the human is administered 150 μg to about 200 μg of PYY(3–36) (SEQ ID NO: 2).
24. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a human comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the human wherein the PYY formulation is comprised of water, chlorobutanol, sodium citrate, citric acid, methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and PYY(3–36) (SEQ ID NO: 2), wherein the formulation has a pH of about 5.0±0.3 and wherein the human is administered 150 μg to about 200 μg of PYY(3–36) (SEQ ID NO: 2).
25. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a human comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the human wherein the PYY formulation is comprised of water, benzalkonium chloride, sodium citrate, citric acid, methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and PYY(3–36) (SEQ ID NO: 2), wherein the formulation has a pH of about 5.0±0.3 and wherein the human is administered 150 μg to about 200 μg of PYY(3–36) (SEQ ID NO: 2).
26. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a human comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the human wherein the PYY formulation is comprised of water, chlorobutanol, sodium citrate, citric acid, methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and PYY(3–36) (SEQ ID NO: 2), wherein the formulation has a pH of about 5.0±0.3.
27. A method for treating obesity, inducing weight-loss, inducing satiety or inducing appetite suppression in a human comprising administering intranasally a therapeutically effective amount of a peptide YY (PYY) formulation to the human wherein the PYY formulation is comprised of water, benzalkonium chloride, sodium citrate, citric acid, methyl-β-cyclodextrin, EDTA, lactose, sorbitol, L-α-phosphatidylcholine didecanoyl and PYY(3–36) (SEQ ID NO: 2), wherein the formulation has a pH of about 5.0±0.3.